Objective: To compare LNG-IUS and oral tranexamic acid in dis-functional uterine bleeding (DUB) therapy in terms of efficacy in reducing blood loss during menstruation, side effects, and comp-liance with therapy.Material and Methods: 60 patients who were diagnosed with DUB and were treated with either oral tranexamic acid 3gr/day or LNG-IUS were included in the study. Bleeding scores (PBAS), duration of bleeding and haemoglobin values before the therapy were recorded. Patients were evaluated again for the same pa-rameters and possible side effects on the 3rd and 6th months of therapy.Results: Decrease in duration of bleeding on the 3rd and 6th months of therapy were statistically significant in both groups (p0,05), the decrease was more significant in the LNG-IUS group than the tranexamic acid group on the 6th month (p0,05). In the LNG-IUS group, PBAS decreased by 87.5 % on the 3rd month, and 90.5% on the 6th month, and these changes were statistically significant (p
Amaç: Disfonksiyonel uterin kanama (DUK) tedavisinde LNG-I-US (Levonergestrel salgılayan intrauterin sistem) ve oral tranek-samik asit menstrüel kan kaybını azaltmadaki etkinliği, yan etkiler ve tedaviye devam açısından karşılaştırılmıştır.Gereç ve Yöntemler: Çalışmaya DUK tanısı alıp LNG-IUS uygu-lanan ve 3 gr/gün oral traneksamik asit kullanan toplam 60 hasta dahil edildi. Hastaların gözlemsel kanama skorlama sistemi ile hesaplanmış tedavi öncesi kanama skorları (PBAS), kanamalı gün sayıları ve hemoglobin değerleri kaydedildi. Hastalar tedavinin 3 ve 6. aylarında çağrılarak kanama skorları (PBAS), kanamalı gün sayıları, hemoglobin değerleri kaydedilip, yan etkiler açısından ayrıntılı sorgulandı.Bulgular: İki gruptada 3 ve 6. ayda kanamalı gün sayısındaki azalma istatiksel olarak anlamlıdır (p0,05), 6. ayda LNG-IUS grubunda-ki azalma traneksamik asit grubundaki azalmadan daha fazladır (p0,05). LNG-IUS grubunda PBAS’de 3. ayda %87,5 ve 6. ayda %90,5 azalma olup, 6. aydaki azalma istatiksel olarak daha fazladır (p
___
1. Fraser IS, Inceboz US. Defining disturbances of the menstrual cycle. In: O’Brien S, Maclean A, Cameron I, eds. Disorders of themenstrual cycle. London: RCOG Press, 2000; 141–52.
2. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988–1990. Obstet Gynecol 1994; 83: 549–55.
3. Kjerulff KH, Langenberg PW, Rhodes JC, Harvey LA, Guzinski GM, Stolley PD. Effectiveness of hysterectomy. Obstet Gynecol 2000; 95: 319–26.
4. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women’s Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994; 83:556–65.
5. Brooks PG, Clouse J, Morris LS. Hysterectomy vs. resectoscopic endometrial ablation for the control of abnormal uterine bleeding. A cost comparative study. J Reprod Med 1994; 39: 755–60.
6. Sandra E Brooks 1, C Daniel Mullins, Chuanfa Guo, T Timothy Chen, James F Gardner, Claudia R Baquet. Resource utilization for patients undergoing hysterectomy with or without lymph node dissection for` endometrial cancer. Gynecol Oncol 2002; 85: 242–9.
7. Broder MS, Kanouse DE, Mittman BS, Bernstein SJ. The appropriateness of recommendations for hysterectomy. Obstet Gynecol 2000; 95: 199–205.
8. Janssen CA, Scholten PC, Heintz APM. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977–82.
9. Lobo RA, Picker JH, Wild RA, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95.
10. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR et al. The Postmenopausal Estrogen/Progestin Intervention Study; primary outcome in adherent women. Maturitas 1997; 27: 261–74.
11. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J 1996; 313: 579–82.
12. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970; 4: 214–16.
13. Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995; 11: 456–71.
14. Milsom I, Anderson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879–83.
15. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006; 26: 673–8.
16. Luukkainen T, Pakarinen P, Toivonen J. Progestin releasing intrauterine systems. Semin Reprod Med 2001; 19: 355–63.
17. Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyörälä T, Terho J et al. Effective contraception with the levonorgestrel-releasing intrauterine device. 12 month report of a European multicenter study. Contraception 1987; 36: 169–79.
18. Stewart A, Cummins C, Gold L. The effectiveness of the levonorgestrel- releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001; 108: 74–86.
19. Milsom I, Anderson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879–83.
20. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73: 274–7.